JP2022505923A5 - - Google Patents

Info

Publication number
JP2022505923A5
JP2022505923A5 JP2021523009A JP2021523009A JP2022505923A5 JP 2022505923 A5 JP2022505923 A5 JP 2022505923A5 JP 2021523009 A JP2021523009 A JP 2021523009A JP 2021523009 A JP2021523009 A JP 2021523009A JP 2022505923 A5 JP2022505923 A5 JP 2022505923A5
Authority
JP
Japan
Prior art keywords
invention described
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021523009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022505923A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/059556 external-priority patent/WO2020093024A2/en
Publication of JP2022505923A publication Critical patent/JP2022505923A/ja
Publication of JP2022505923A5 publication Critical patent/JP2022505923A5/ja
Pending legal-status Critical Current

Links

JP2021523009A 2018-11-01 2019-11-01 抗tim-3抗体を投与する方法 Pending JP2022505923A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862754378P 2018-11-01 2018-11-01
US62/754,378 2018-11-01
PCT/US2019/059556 WO2020093024A2 (en) 2018-11-01 2019-11-01 Methods of administering anti-tim-3 antibodies

Publications (2)

Publication Number Publication Date
JP2022505923A JP2022505923A (ja) 2022-01-14
JP2022505923A5 true JP2022505923A5 (cg-RX-API-DMAC7.html) 2022-11-08

Family

ID=69159932

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523009A Pending JP2022505923A (ja) 2018-11-01 2019-11-01 抗tim-3抗体を投与する方法

Country Status (8)

Country Link
US (1) US20220073616A1 (cg-RX-API-DMAC7.html)
EP (1) EP3873612A2 (cg-RX-API-DMAC7.html)
JP (1) JP2022505923A (cg-RX-API-DMAC7.html)
CN (1) CN113301961A (cg-RX-API-DMAC7.html)
AU (1) AU2019372436A1 (cg-RX-API-DMAC7.html)
CA (1) CA3117371A1 (cg-RX-API-DMAC7.html)
IL (1) IL282708A (cg-RX-API-DMAC7.html)
WO (1) WO2020093024A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200231652A1 (en) 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
IL268995B2 (en) 2017-03-02 2024-02-01 Nat Res Council Canada TGF-B receptor ectodomain fusion compounds and their uses
CA3183673A1 (en) * 2020-06-26 2021-12-30 Robert Allen Oncolytic herpes simplex viruses (hsv) expressing immunomodulatory fusion proteins
JP2024514590A (ja) * 2021-04-13 2024-04-02 メディミューン,エルエルシー Pd-1及びtim-3を標的化する二重特異性抗体
CN117377692A (zh) 2021-04-23 2024-01-09 苏州逻晟生物医药有限公司 Tim-3-靶向抗体及其用途
WO2022271917A1 (en) * 2021-06-24 2022-12-29 Bristol-Myers Squibb Company Transforming growth factor-beta ligand traps for the treatment of disease
CN116688115B (zh) * 2022-03-18 2024-02-06 上海齐鲁制药研究中心有限公司 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5179689B2 (ja) 2000-02-11 2013-04-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体ベース融合タンパク質の循環系内半減期の増強
DK1366067T3 (da) 2001-03-07 2012-10-22 Merck Patent Gmbh Ekspressionsteknologi for proteiner indeholdende en hybrid isotype-antistof-enhed
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
US7919092B2 (en) * 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
HRP20210977T1 (hr) 2014-02-10 2021-09-17 Merck Patent Gmbh Ciljano inhibiranje tgf beta
DK3169706T3 (da) * 2014-07-11 2020-03-09 Genmab As Antistoffer, der binder axl
SG11201702401RA (en) * 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
US20180207273A1 (en) * 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CN109414500B (zh) * 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
US10988465B2 (en) * 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
JOP20190013A1 (ar) * 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
MA50677A (fr) * 2016-11-01 2021-07-14 Anaptysbio Inc Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3)
TW201825513A (zh) * 2016-11-29 2018-07-16 美商提薩羅有限公司 針對t細胞免疫球蛋白及黏蛋白3(tim-3)之抗體
CN110050000B (zh) 2017-05-12 2022-07-26 苏州盛迪亚生物医药有限公司 含有TGF-β受体的融合蛋白及其医药用途

Similar Documents

Publication Publication Date Title
JP2023526975A5 (cg-RX-API-DMAC7.html)
JP2020040981A5 (cg-RX-API-DMAC7.html)
JP2020007340A5 (cg-RX-API-DMAC7.html)
JP2021151238A5 (cg-RX-API-DMAC7.html)
JP2021184963A5 (cg-RX-API-DMAC7.html)
JP2020534795A5 (cg-RX-API-DMAC7.html)
JPWO2020148954A5 (cg-RX-API-DMAC7.html)
JP2020042034A5 (cg-RX-API-DMAC7.html)
JP2021048879A5 (cg-RX-API-DMAC7.html)
JP2022122972A5 (cg-RX-API-DMAC7.html)
JP2022541332A5 (cg-RX-API-DMAC7.html)
JP2021518389A5 (cg-RX-API-DMAC7.html)
JP2022185040A5 (cg-RX-API-DMAC7.html)
JP2024026077A5 (cg-RX-API-DMAC7.html)
JP2019030304A5 (cg-RX-API-DMAC7.html)
JP2023514727A5 (cg-RX-API-DMAC7.html)
JP2017214405A5 (cg-RX-API-DMAC7.html)
JP2018154848A5 (cg-RX-API-DMAC7.html)
JP2023552816A5 (cg-RX-API-DMAC7.html)
JP2021100406A5 (cg-RX-API-DMAC7.html)
JP2023182571A5 (cg-RX-API-DMAC7.html)
JP2022064180A5 (cg-RX-API-DMAC7.html)
JP2021524864A5 (cg-RX-API-DMAC7.html)
JP2022505925A5 (cg-RX-API-DMAC7.html)
JP2020079331A5 (cg-RX-API-DMAC7.html)